|
|
|
|
|
(State or other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
| Item 2.02. |
Results of Operations and Financial Condition.
|
| Item 7.01. |
Regulation FD Disclosure.
|
| Item 9.01. |
Financial Statements and Exhibits.
|
| (d) |
Exhibits
|
|
Press Release dated November 08, 2023
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
TURNING POINT BRANDS, INC.
|
|||
|
Dated: November 08, 2023
|
By:
|
/s/ Brittani N. Cushman
|
|
|
Brittani N. Cushman
|
|||
|
Senior Vice President, General Counsel and Secretary
|
|||
| • |
Total consolidated net sales decreased 5.6% to $101.7 million
|
| o |
Zig-Zag Products net sales decreased by 10.2% but stable sequentially
|
| o |
Stoker’s Products net sales increased by 10.1%
|
| o |
Creative Distribution Solutions net sales decreased by 18.7%
|
| • |
Gross profit decreased 2.1% to $51.6 million
|
| • |
Net income decreased 6.1% to $10.8 million
|
| • |
Adjusted net income increased 1.6% to $14.5 million (see Schedule B for a reconciliation to net income)
|
| • |
Adjusted EBITDA decreased 0.4% to $24.4 million (see Schedule A for a reconciliation to net income)
|
| • |
Diluted EPS of $0.58 and Adjusted Diluted EPS of $0.76 compared to $0.60 and $0.72 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)
|
| • |
$1.8 million of stock options, restricted stock and incentive expense compared to $1.4 million in the year-ago period
|
| • |
$0.3 million of FDA PMTA-related expenses for modern oral products compared to $1.2 million in the year-ago period
|
| • |
$0.2 million of restructuring costs related to CDS as compared to $0.0 million in the year-ago period
|
| • |
$0.1 million of transaction expenses compared to $0.0 million in the year-ago period
|
| • |
$0.1 million of ERP / CRM duplicative system costs compared to $0.4 million of ERP / CRM scoping expenses in the previous year
|
|
Three Months Ended September 30,
|
||||||||
|
2023
|
2022
|
|||||||
|
Net sales
|
$
|
101,722
|
$
|
107,802
|
||||
|
Cost of sales
|
50,100
|
55,090
|
||||||
|
Gross profit
|
51,622
|
52,712
|
||||||
|
Selling, general, and administrative expenses
|
31,385
|
32,891
|
||||||
|
Operating income
|
20,237
|
19,821
|
||||||
|
Interest expense, net
|
3,984
|
4,802
|
||||||
|
Investment loss (gain)
|
2,101
|
(75
|
)
|
|||||
|
Gain on extinguishment of debt
|
(481
|
)
|
-
|
|||||
|
Income before income taxes
|
14,633
|
15,094
|
||||||
|
Income tax expense
|
3,767
|
3,797
|
||||||
|
Consolidated net income
|
10,866
|
11,297
|
||||||
|
Net gain (loss) attributable to non-controlling interest
|
35
|
(239
|
)
|
|||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
10,831
|
$
|
11,536
|
||||
|
Basic income per common share:
|
||||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.62
|
$
|
0.65
|
||||
|
Diluted income per common share:
|
||||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.58
|
$
|
0.60
|
||||
|
Weighted average common shares outstanding:
|
||||||||
|
Basic
|
17,595,980
|
17,749,294
|
||||||
|
Diluted
|
20,098,450
|
21,102,006
|
||||||
|
Supplemental disclosures of statements of income information:
|
||||||||
|
Excise tax expense
|
$
|
5,288
|
$
|
5,747
|
||||
|
FDA fees
|
$
|
142
|
$
|
170
|
||||
|
ASSETS
|
(unaudited)
September 30,
2023
|
December 31,
2022
|
||||||
|
Current assets:
|
||||||||
|
Cash
|
$
|
96,071
|
$
|
106,403
|
||||
|
Accounts receivable, net of allowances of $59 in 2023 and $114 in 2022
|
10,493
|
8,377
|
||||||
|
Inventories
|
116,926
|
119,915
|
||||||
|
Other current assets
|
23,322
|
22,959
|
||||||
|
Total current assets
|
246,812
|
257,654
|
||||||
|
Property, plant, and equipment, net
|
24,613
|
22,788
|
||||||
|
Deferred income taxes
|
8,190
|
8,443
|
||||||
|
Right of use assets
|
12,060
|
12,465
|
||||||
|
Deferred financing costs, net
|
203
|
282
|
||||||
|
Goodwill
|
136,280
|
136,253
|
||||||
|
Other intangible assets, net
|
81,725
|
83,592
|
||||||
|
Master Settlement Agreement (MSA) escrow deposits
|
27,534
|
27,980
|
||||||
|
Other assets
|
16,526
|
22,649
|
||||||
|
Total assets
|
$
|
553,943
|
$
|
572,106
|
||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
11,237
|
$
|
8,355
|
||||
|
Accrued liabilities
|
27,227
|
33,001
|
||||||
|
Current portion of long-term debt
|
48,248
|
-
|
||||||
|
Other current liabilities
|
6
|
20
|
||||||
|
Total current liabilities
|
86,718
|
41,376
|
||||||
|
Notes payable and long-term debt
|
316,573
|
406,757
|
||||||
|
Lease liabilities
|
10,433
|
10,593
|
||||||
|
Total liabilities
|
413,724
|
458,726
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders' equity:
|
||||||||
|
Preferred stock; $0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-
|
-
|
-
|
||||||
|
Common stock, voting, $0.01 par value; authorized shares, 190,000,000; 19,912,882 issued shares and 17,596,422 outstanding shares at September 30, 2023, and 19,801,623 issued shares and
17,485,163 outstanding shares at December 31, 2022
|
|
199
|
198
|
|||||
|
Common stock, nonvoting, $0.01 par value; authorized shares, 10,000,000; issued and outstanding shares
-0-
|
|
-
|
-
|
|||||
|
Additional paid-in capital
|
|
117,143
|
113,242
|
|||||
|
Cost of repurchased common stock (2,316,460 shares at September 30, 2023 and December 31, 2022)
|
(78,093
|
)
|
(78,093
|
)
|
||||
|
Accumulated other comprehensive loss
|
(3,855
|
)
|
(2,393
|
)
|
||||
|
Accumulated earnings
|
103,517
|
78,691
|
||||||
|
Non-controlling interest
|
1,308
|
1,735
|
||||||
|
Total stockholders' equity
|
140,219
|
113,380
|
||||||
|
Total liabilities and stockholders' equity
|
$
|
553,943
|
$
|
572,106
|
||||
|
Nine Months Ended September 30,
|
||||||||
|
2023
|
2022
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Consolidated net income
|
$
|
27,916
|
$
|
27,274
|
||||
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
|
Gain on extinguishment of debt
|
(1,858
|
)
|
-
|
|||||
|
Loss (gain) on sale of property, plant, and equipment
|
34
|
(8
|
)
|
|||||
|
Depreciation and other amortization expense
|
2,388
|
2,611
|
||||||
|
Amortization of other intangible assets
|
2,315
|
1,373
|
||||||
|
Amortization of deferred financing costs
|
1,795
|
1,936
|
||||||
|
Deferred income tax expense (benefit)
|
694
|
(431
|
)
|
|||||
|
Stock compensation expense
|
4,660
|
4,103
|
||||||
|
Noncash lease income
|
(48
|
)
|
-
|
|||||
|
Loss on investments
|
11,162
|
6,244
|
||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
(2,112
|
)
|
(5,030
|
)
|
||||
|
Inventories
|
3,036
|
(26,467
|
)
|
|||||
|
Other current assets
|
(1,384
|
)
|
1,891
|
|||||
|
Other assets
|
(5,110
|
)
|
1,211
|
|||||
|
Accounts payable
|
2,865
|
2,074
|
||||||
|
Accrued liabilities and other
|
(6,348
|
)
|
(392
|
)
|
||||
|
Net cash provided by operating activities
|
$
|
40,005
|
$
|
16,389
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Capital expenditures
|
$
|
(4,206
|
)
|
$
|
(6,662
|
)
|
||
|
Payments for investments
|
(200
|
)
|
(1,000
|
)
|
||||
|
Restricted cash, MSA escrow deposits
|
-
|
(10,169
|
)
|
|||||
|
Proceeds on the sale of property, plant and equipment
|
3
|
63
|
||||||
|
Net cash used in investing activities
|
$
|
(4,403
|
)
|
$
|
(17,768
|
)
|
||
|
Cash flows from financing activities:
|
||||||||
|
Repurchased Convertible Senior Notes
|
$
|
(41,794
|
)
|
$
|
-
|
|||
|
Proceeds from call options
|
114
|
-
|
||||||
|
Payment of dividends
|
(3,354
|
)
|
(3,259
|
)
|
||||
|
Exercise of options
|
419
|
504
|
||||||
|
Redemption of options
|
(346
|
)
|
(155
|
)
|
||||
|
Redemption of performance restricted stock units
|
(995
|
)
|
(1,228
|
)
|
||||
|
Common stock repurchased
|
-
|
(27,032
|
)
|
|||||
|
Net cash used in financing activities
|
$
|
(45,956
|
)
|
$
|
(31,170
|
)
|
||
|
Net decrease in cash
|
$
|
(10,354
|
)
|
$
|
(32,549
|
)
|
||
|
Effect of foreign currency translation on cash
|
$
|
22
|
$
|
(324
|
)
|
|||
|
Cash, beginning of period:
|
||||||||
|
Unrestricted
|
$
|
106,403
|
$
|
128,320
|
||||
|
Restricted
|
4,929
|
15,155
|
||||||
|
Total cash at beginning of period
|
$
|
111,332
|
$
|
143,475
|
||||
|
Cash, end of period:
|
||||||||
|
Unrestricted
|
$
|
96,071
|
$
|
105,672
|
||||
|
Restricted
|
4,929
|
4,930
|
||||||
|
Total cash at end of period
|
$
|
101,000
|
$
|
110,602
|
||||
|
Three Months Ended
September 30,
|
||||||||
|
2023
|
2022
|
|||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
10,831
|
$
|
11,536
|
||||
|
Add:
|
||||||||
|
Interest expense, net
|
3,984
|
4,802
|
||||||
|
Gain on extinguishment of debt
|
(481
|
)
|
-
|
|||||
|
Income tax expense
|
3,767
|
3,797
|
||||||
|
Depreciation expense
|
782
|
861
|
||||||
|
Amortization expense
|
844
|
454
|
||||||
|
EBITDA
|
$
|
19,727
|
$
|
21,450
|
||||
|
Components of Adjusted EBITDA
|
||||||||
|
Corporate restructuring (a)
|
190
|
17
|
||||||
|
ERP/CRM (b)
|
138
|
435
|
||||||
|
Stock options, restricted stock, and incentives expense (c)
|
1,824
|
1,442
|
||||||
|
Transactional expenses (d)
|
76
|
-
|
||||||
|
FDA PMTA (e)
|
275
|
1,169
|
||||||
|
Non-cash asset impairment (f)
|
2,173
|
-
|
||||||
|
Adjusted EBITDA
|
$
|
24,403
|
$
|
24,513
|
||||
| (a) |
Represents costs associated with corporate restructuring, including severance.
|
| (b) |
Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.
|
| (c) |
Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units ("PRSUs").
|
| (d) |
Represents the fees incurred for transaction expenses.
|
| (e) |
Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA").
|
| (f) |
Represents impairment of investment assets.
|
|
Three Months Ended
September 30, 2023
|
Three Months Ended
September 30, 2022
|
|||||||||||||||
|
Net Income
|
Diluted EPS
|
Net Income
|
Diluted EPS
|
|||||||||||||
|
GAAP EPS
|
$
|
10,831
|
$
|
0.58
|
$
|
11,536
|
$
|
0.60
|
||||||||
|
Gain on extinguishment of debt (a)
|
(357
|
)
|
(0.02
|
)
|
-
|
-
|
||||||||||
|
Corporate restructuring (b)
|
141
|
0.01
|
13
|
0.00
|
||||||||||||
|
ERP/CRM (c)
|
102
|
0.01
|
326
|
0.02
|
||||||||||||
|
Stock options, restricted stock, and incentives expense (d)
|
1,354
|
0.07
|
1,079
|
0.05
|
||||||||||||
|
Transactional expenses (e)
|
56
|
0.00
|
-
|
-
|
||||||||||||
|
FDA PMTA (f)
|
204
|
0.01
|
875
|
0.04
|
||||||||||||
|
Non-cash asset impairment (g)
|
1,614
|
0.08
|
-
|
-
|
||||||||||||
|
Tax benefit (h)
|
575
|
0.03
|
469
|
0.01
|
||||||||||||
|
Adjusted
|
$
|
14,521
|
$
|
0.76
|
$
|
14,297
|
$
|
0.72
|
||||||||
| (a) |
Represents gain on extinguishment of debt tax effected at the quarterly tax rate.
|
| (b) |
Represents costs associated with corporate restructuring, including severance, tax effected at the quarterly tax rate.
|
| (c) |
Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses tax effected at the quarterly tax rate.
|
| (d) |
Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly tax rate.
|
| (e) |
Represents the fees incurred for transaction expenses tax effected at the quarterly tax rate.
|
| (f) |
Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly tax rate.
|
| (g) |
Represents impairment of investment assets tax effected at the quarterly tax rate.
|
| (h) |
Represents adjustment from quarterly tax rate to annual projected tax rate of 23% in 2023 and 2022.
|
|
Consolidated
|
Zig-Zag Products
|
Stoker's Products
|
Creative Distribution Solutions
|
|||||||||||||||||||||||||||||
|
3rd Quarter
2023
|
3rd Quarter
2022
|
3rd Quarter
2023
|
3rd Quarter
2022
|
3rd Quarter
2023
|
3rd Quarter
2022
|
3rd Quarter
2023
|
3rd Quarter
2022
|
|||||||||||||||||||||||||
|
Net sales
|
$
|
101,722
|
$
|
107,802
|
$
|
46,754
|
$
|
52,061
|
$
|
36,916
|
$
|
33,525
|
$
|
18,052
|
$
|
22,216
|
||||||||||||||||
|
Gross profit
|
$
|
51,622
|
$
|
52,712
|
$
|
26,745
|
$
|
28,035
|
$
|
20,572
|
$
|
18,279
|
$
|
4,305
|
$
|
6,398
|
||||||||||||||||
|
Operating income (loss)
|
$
|
20,237
|
$
|
19,821
|
$
|
16,672
|
$
|
18,740
|
$
|
15,703
|
$
|
13,653
|
$
|
(460
|
)
|
$
|
142
|
|||||||||||||||
|
Adjustments:
|
||||||||||||||||||||||||||||||||
|
Corporate restructuring
|
190
|
17
|
-
|
-
|
-
|
-
|
190
|
-
|
||||||||||||||||||||||||
|
ERP/CRM
|
138
|
435
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
Transactional expenses
|
76
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
FDA PMTA
|
275
|
1,169
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
Adjusted operating income (loss)
|
$
|
20,916
|
$
|
21,442
|
$
|
16,672
|
$
|
18,740
|
$
|
15,703
|
$
|
13,653
|
$
|
(270
|
)
|
$
|
142
|
|||||||||||||||